RecruitingNCT07069400

An International Observational Study of Adults With Acute Infection


Sponsor

University of Minnesota

Enrollment

1,500 participants

Start Date

Aug 25, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

Prospective, longitudinal studies of people with acute infections are essential to understand risk factors, clinical manifestations, pathobiology, and management strategies. Observational studies can provide data necessary to select interventions and strategies for testing in clinical trials and to develop key design features of trials. Observational studies can be particularly important for establishing an early knowledge base after emergence of a new pathogen, as illustrated by the recent emergence of influenza A (H1N1), SARS-CoV-2, and Mpox. This observational study protocol describes collection of data and biospecimens from sites across the world for characterizing acute infections in hospitalized patients. The protocol is designed to study respiratory infections, infections outside the respiratory tract, established infectious diseases, and emerging infectious diseases. Data generated in this study will be used to efficiently characterize acute infectious diseases and plan future clinical trials.


Eligibility

Min Age: 18 Years

Inclusion Criteria4

  • Age ≥18 years old
  • Admitted to hospital (or in an emergency department with anticipated hospital admission) for the management of a suspected or confirmed acute infectious disease.
  • Onset of symptoms of an infectious disease within the past 30 days.
  • Informed consent for study participation by the participant or a surrogate decision maker if the participant lacks capacity for consent.

Exclusion Criteria4

  • Current imprisonment (this does not include quarantine for an infectious disease).
  • Patient undergoing comfort care measures only such that treatment focuses on end- of-life symptom management over prolongation of life.
  • Expected inability or unwillingness to participate in study procedures.
  • In the opinion of the investigator, participation in the study is not in the best interest of the patient.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERNo intervention

This is an observational study


Locations(47)

Banner University Medical Center Tucson

Tucson, Arizona, United States

Stanford University Hospital & Clinics (Site 203-003)

Palo Alto, California, United States

UCSF Medical Center (Site 203-001)

San Francisco, California, United States

Orlando VA Medical Center (074-032)

Orlando, Florida, United States

University of Illinois at Chicago (Site 008-012)

Chicago, Illinois, United States

University of Kansas Medical Center (Site 080-044)

Kansas City, Kansas, United States

University of Minnesota

Minneapolis, Minnesota, United States

Mayo Clinic (Site 054-001)

Rochester, Minnesota, United States

University of Nebraska Medical Center (Site 080-045)

Omaha, Nebraska, United States

New York University Langone Health (301-013)

New York, New York, United States

Mount Sinai Medical Center (Site 301-012)

New York, New York, United States

Duke University (301-006)

Durham, North Carolina, United States

Wake Forest Baptist Health (210-001)

Winston-Salem, North Carolina, United States

Cleveland Clinic Foundation (Site 207-001)

Cleveland, Ohio, United States

Vanderbilt University Medical Center (Site 212-001)

Nashville, Tennessee, United States

UT Southwestern Medical Center (084-001)

Dallas, Texas, United States

Intermountain Medical Center (Site 211-001)

Murray, Utah, United States

West Virginia University Medicine (301-023)

Morgantown, West Virginia, United States

Instituto Medico Platense (611-025)

La Plata, Buenos Aires, Argentina

Hospital General de Agudos JM Ramos Mejia (Site 611-001)

Buenos Aires, Argentina

Royal Prince Alfred Hospital (612-056)

Camperdown, New South Wales, Australia

St. Vincent's Hospital (612-002)

Sydney, New South Wales, Australia

Westmead Hospital (Site 612-058)

Westmead, New South Wales, Australia

Royal Brisbane and Women's Hospital (Site 612-055)

Brisbane, Queensland, Australia

Monash Health (612-009)

Clayton, Victoria, Australia

Austin Health (Site 612-020)

Heidelberg, Victoria, Australia

The Alfred Hospital (Site 612-017)

Melbourne, Victoria, Australia

The Royal Melbourne Hospital (612-025)

Parkville, Victoria, Australia

Associaco Beneficente Siria - HCor (649-203)

São Paulo, São Paulo, Brazil

CERMIPA (Site 403-001)

Abidjan, Côte d’Ivoire

Rigshospitalet, CHIP (625-006)

Copenhagen, Denmark

Hospices Civiles de Lyon (631-033)

Lyon, France

Hospital St Louis (631-019)

Paris, France

Klinik I fur Innere Medizin der Universitat zu Koln (622-008)

Cologne, Germany

Evangelismos General Hospital (Site 635-020)

Athens, Attica, Greece

3rd Dept of Medicine, Medical School (Site 635-022)

Athens, Attica, Greece

Fujita Health University Hospital

Toyoake, Aichi-ken, Japan

Japan Institute for Health Security

Tokyo, Japan

Tan Tock Seng Hospital

Singapore, Singapore

Seoul National University Bundang Hospital

Seongnam-si, Gyeonggi-do, South Korea

Seoul St. Mary's Hospital

Seoul, South Korea

Hospital Universitari Germans Trias i Pujol (Site 626-003)

Badalona, Barcelona, Spain

Chulalongkorn University and The HIV-NAT (Site 613-001)

Bangkok, Thailand

MRC/UVRI & LSHTM Uganda Research Unit (Site 634-601)

Entebbe, Uganda

Lira Regional Referral Hospital (Site 634-605)

Lira, Uganda

Central City Clinical Hospital of Ivano-Frankivsk City Council (627-302)

Ivano-Frankivsk, Ukraine

Royal Free Hospital (Site 634-006)

London, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07069400


Related Trials